slu pp 332 vs retatrutide Reta rats let’s get it: 332, https://drive.google.com/drive/folders/13bl6fM6K_NAlHpvlDWnfKM_oEdiKD6zL?usp=sharing, You can find everything in here and the excel with papers will update everyday SLU-PP-332 – Peptidnova

Matthew R Hayes, Heath D Schmidt, GLP-1 influences food and drug reward, Current Opinion in Behavioral Sciences, Volume 9, 2016, Pages 66-70, ISSN 2352-1546 Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J

retatrutide research uk At the highest investigational dose (12 mg weekly): Mean weight reduction reached 24.2% at 48 weeks Weight loss continued progressively without plateau Dose-dependent efficacy was observed across cohorts Additional metabolic improvements included: Significant reductions in BMI Reduced waist circumference Lower fasting plasma glucose Meaningful HbA1c improvements Blood pressure reductions A pooled meta-analysis of randomised controlled trials confirmed statistically significant improvements in: Body weight (14.33% vs placebo) BMI (5.38 difference) Waist circumference (10.51 cm) Fasting glucose HbA1c (0.91%) Systolic and diastolic blood pressure Importantly, these improvements were achieved through combined appetite suppression and increased energy expenditure a dual mechanism not fully realised in earlier incretin therapies

Incretin based therapies such as GLP-1 receptor agonists have revolutionised management of type 2 diabetes by enhancing insulin secretion, slowing gastric emptying and reducing appetite (Dungan & DeSantis, 2025)

A meta-analysis of 10 trials totaling 71,351 patients extended these findings, showing GLP-1 receptor agonists reduced the composite kidney outcome by 17% across trials

Always solve for mg/mL first, then derive injection volume from that concentration

I dont trust weight-loss supplements, he says